- Home
- TKC vs PTGX Comparison
TKC vs PTGX Comparison
Compare TKC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKC | PTGX |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.2B |
| IPO Year | 2001 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TKC | PTGX |
|---|---|---|
| Price | $6.46 | $98.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $108.23 |
| AVG Volume (30 Days) | ★ 929.7K | 620.5K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.20 | $874.25 |
| Revenue Next Year | $24.27 | N/A |
| P/E Ratio | $26.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $41.29 |
| 52 Week High | $7.18 | $107.84 |
Technical Indicators
Market Signals| Indicator | TKC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 56.01 | 46.91 |
| Support Level | $6.44 | $95.40 |
| Resistance Level | $6.68 | $100.00 |
| Average True Range (ATR) | 0.11 | 4.31 |
| MACD | 0.01 | -0.83 |
| Stochastic Oscillator | 54.17 | 36.81 |
Price Performance
Historical ComparisonAbout TKC Turkcell Iletisim Hizmetleri AS
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.